Results

RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/SHA-384/5E560E19BE4724A2EDB69E93396422CF61316331ED5A073C5C460510D90B14C8DC15AEA2D21F0E606CDEA3E5EF168402http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/5E560E19BE4724A2EDB69E93396422CF61316331ED5A073C5C460510D90B14C8DC15AEA2D21F0E606CDEA3E5EF168402http://www.w3.org/2000/01/rdf-schema#comment"Carriers of 719Arg receive significantly greater benefit from intensive statin therapy than do noncarriers a superior benefit that appears to be due to a mechanism distinct from lipid or CRP lowering; Clinical trial of gene-environment interaction and pharmacogenomic / toxicogenomic. (HuGE Navigator)"xsd:string
http://purl.uniprot.org/uniprot/#_83A54C4AF3DBADBF1932B9FE9C9A09FABADE7911FC538119EA4F1EC4C1C3DB318A5C9D0E539F06C764579056BECD77F4http://www.w3.org/1999/02/22-rdf-syntax-ns#subjecthttp://purl.uniprot.org/SHA-384/5E560E19BE4724A2EDB69E93396422CF61316331ED5A073C5C460510D90B14C8DC15AEA2D21F0E606CDEA3E5EF168402
http://purl.uniprot.org/uniprot/Q6ZMV9http://purl.uniprot.org/core/mappedAnnotationhttp://purl.uniprot.org/SHA-384/5E560E19BE4724A2EDB69E93396422CF61316331ED5A073C5C460510D90B14C8DC15AEA2D21F0E606CDEA3E5EF168402
http://purl.uniprot.org/uniprot/#_Q6ZMV9-mappedCitation-18222355http://purl.uniprot.org/core/mappedAnnotationhttp://purl.uniprot.org/SHA-384/5E560E19BE4724A2EDB69E93396422CF61316331ED5A073C5C460510D90B14C8DC15AEA2D21F0E606CDEA3E5EF168402